$11.14−0.16 (−1.42%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
NovoCure (NVCR) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~5.2%/yr (FY21→FY25), net margin −20.8%. Worth your attention in FY25: Share count (+7.8%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲8.3%
655.4
FY21→FY25CAGR +5.2%/yr
Net income ($M)▲19.2%
−136.2
one-off year: see footnoteCAGR —
Free cash flow ($M)▼9.3%
−75.7
FY21→FY25CAGR —
Diluted EPS▲21.8%
−1.22
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+7.8%
103.4mn → 111.5mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$26.6M
−37.8% YoY in FY25 · 4.1% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-21¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 78.5% → 74.5%. Net margin -20.8% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 725,388.0 | 655,353.0 | 605,220.0 | 509,338.0 | 537,840.0 | 535,031.0 | ▲8.3% | +5.2% |
Cost of revenue | 166,721.0 | 166,879.0 | 137,181.0 | 128,280.0 | 114,867.0 | 114,877.0 | ▲21.6% | +9.8% |
Gross profit | 558,667.0 | 488,474.0 | 468,039.0 | 381,058.0 | 422,973.0 | 420,154.0 | ▲4.4% | +3.8% |
Research & development | 228,788.0 | 224,544.0 | 209,645.0 | 223,062.0 | 206,085.0 | 201,303.0 | ▲7.1% | +2.8% |
Selling, general & admin | 212,427.0 | 177,666.0 | 189,827.0 | 164,057.0 | 132,753.0 | 126,127.0 | ▼6.4% | +8.9% |
Total operating expenses | 683,213.0 | 642,274.0 | 638,535.0 | 613,928.0 | 512,496.0 | 464,487.0 | ▲0.6% | +8.4% |
Operating incomefeeds ROC rank | −124,546.0 | −153,800.0 | −170,496.0 | −232,870.0 | −89,523.0 | −44,333.0 | ▲9.8% | — |
Other income, net | −5,998.0 | 17,550.0 | 39,334.0 | 41,130.0 | 7,677.0 | −7,742.0 | — | — |
Pretax income | −130,544.0 | −136,250.0 | −131,162.0 | −191,740.0 | −81,846.0 | −52,075.0 | ▼3.9% | — |
Income tax | −8,814.0 | −23.0 | 37,465.0 | 15,303.0 | 10,688.0 | 6,276.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −121,730.0 | −136,227.0 | −168,627.0 | −207,043.0 | −92,534.0 | −58,351.0 | ▲19.2% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.06 | −1.22 | −1.56 | −1.95 | −0.88 | −0.56 | ▲21.8% | — |
Diluted shares (mn) | 116.79 | 111.47 | 107.83 | 106.39 | 104.66 | 103.43 | ▲3.4% | +1.9% |
| Margins | ||||||||
Gross margin70th pct in Healthcare | 77.0% | 74.5% | 77.3% | 74.8% | 78.6% | 78.5% | ▼2.8pp | −4.0pp |
Operating margin | −17.2% | −23.5% | −28.2% | −45.7% | −16.6% | −8.3% | ▲4.7pp | −15.2pp |
Net margin24th pct in Healthcare | −16.8% | −20.8% | −27.9% | −40.6% | −17.2% | −10.9% | ▲7.1pp | −9.9pp |
† TTM = trailing four quarters through 2026-09-30.FY24 effective tax rate was −29% vs a −12% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was 0% vs a −12% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was NovoCure's revenue last fiscal year?
NovoCure reported revenue of $655.4M in fiscal 2025, up 8.3% from fiscal 2024.
What was NovoCure's net income?
NovoCure reported net income of −$136.2M in fiscal 2025, a net margin of −20.8%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

